^
Association details:
Biomarker:BRAF V600E
Cancer:Melanoma
Drug:navtemadlin (KRT-232) (MDM2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Excerpt:
…BRAFV600E/M PDXs exhibited a synergistic response to the combination of KRT-232 and BRAF/MEK inhibitors.
Secondary therapy:
BRAF inhibitor; MEK inhibitor
DOI:
10.1158/1078-0432.CCR-19-1895